Neuroimaging in dementia and Alzheimer's disease: Current protocols and practice in the Republic of Ireland

被引:2
|
作者
Kelly, I. [1 ]
Butler, M. -L. [1 ]
Ciblis, A. [1 ]
McNulty, J. P. [1 ]
机构
[1] Univ Coll Dublin, Hlth Sci Ctr, Sch Med, Diagnost Imaging, Dublin 4, Ireland
关键词
Alzheimer's disease; Computed tomography; Dementia; Magnetic resonance imaging; Positron emission tomography; Protocols;
D O I
10.1016/j.radi.2015.11.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Neuroimaging plays an essential supportive role in the diagnosis of dementia, assisting in establishing the dementia subtype(s). This has significant value in both treatment and care decisions and has important implications for prognosis. This study aims to explore the development and nature of neuroimaging protocols currently used in the assessment of dementia and Alzheimer's disease (AD). Methods: An online questionnaire was designed and distributed to lead radiography personnel working in computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) departments (n = 94) in both hospital-based and out-patient imaging centres in the Republic of Ireland. Results: Response rates for each modality ranged from 42 to 44%. CT, MRI, and PET were used to specifically diagnose dementia or AD by 43%, 40% and 50% of responding centres respectively. Of these, dementia-specific neuroimaging protocols were utilised in 33%, 50% and 100% of CT, MRI and PET centres respectively, with the remainder using either standard or other non-specific protocols. Both radiologists and clinical specialist radiographers participated in the development of the majority of protocols. The Royal College of Radiologists (RCR) guidelines were most commonly referenced as informing protocol development, however, none of the MRI respondents were able to identify any guidelines used to inform MR protocol development. Conclusion: Currently there is no consensus in Ireland on optimal dementia/AD neuroimaging protocols, particularly for PET and MRI. Similarly the use of validated and published guidelines to inform protocols is not universal. (C) 2015 The College of Radiographers. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 50 条
  • [31] Neuroimaging techniques in Alzheimer's disease
    Frackowiak, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 666 - 666
  • [32] Neuroimaging findings in Alzheimer's disease
    Fukuyama, H
    NEUROPATHOLOGY, 1998, 18 (01) : 91 - 97
  • [33] Alzheimer's disease neuroimaging initiative
    Mueller, Susanne G.
    Weiner, Michael W.
    Thal, Leon J.
    Petersen, Ronald C.
    Jack, Clifford
    Jagust, William
    Trojanowski, John Q.
    Toga, Arthur W.
    Beckett, Laurel
    ADVANCES IN ALZHEIMER'S AND PARKINSON'S DISEASE: INSIGHTS, PROGRESS, AND PERSPECTIVES, 2008, 57 : 183 - 189
  • [34] Molecular Neuroimaging in Alzheimer's Disease
    Matsuda, Hiroshi
    Imabayashi, Etsuko
    NEUROIMAGING CLINICS OF NORTH AMERICA, 2012, 22 (01) : 57 - +
  • [35] Neuroimaging of delusions in Alzheimer's disease
    Ismail, Zahinoor
    Minh-Quan Nguyen
    Fischer, Corinne E.
    Schweizer, Tom A.
    Mulsant, Benoit H.
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2012, 202 (02) : 89 - 95
  • [36] Neuroimaging and early Alzheimer's disease
    Smith, AD
    Jobst, KA
    Edmonds, Z
    Hindley, NJ
    King, EMF
    LANCET, 1996, 348 (9030): : 829 - 830
  • [37] Advances on Alzheimer's Disease With Neuroimaging
    He Yong
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2012, 39 (08) : 811 - 815
  • [38] Neuroimaging biomarkers in Alzheimer's disease
    Nestor, Peter
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [39] Molecular Neuroimaging in Alzheimer's Disease
    Jagust W.
    NeuroRX, 2004, 1 (2): : 206 - 212
  • [40] Neuroimaging Biomarkers for Alzheimer’s Disease
    Freddie Márquez
    Michael A. Yassa
    Molecular Neurodegeneration, 14